SAN DIEGO, June 11, 2018 /PRNewswire/ -- NuVasive, Inc.
(NASDAQ: NUVA), the leader in spine technology innovation, focused
on transforming spine surgery with minimally disruptive,
procedurally-integrated solutions, today announced the appointments
of Lisa Pecora as vice president,
Global Commercial Finance and Tristan
Ribar as vice president, Corporate Finance and Treasury. In
addition, Marc Rosenbaum is promoted
to corporate controller.
As the head of Global Commercial Finance, Ms. Pecora manages the
U.S. and International Commercial finance functions with a focus on
driving revenue growth and go-to-market strategy. Ms. Pecora is a
seasoned finance professional who most recently served as executive
vice president and chief financial officer of Carling
Communications. In this role, she oversaw all financial and
operational functions across the three companies that comprised the
Carling Group of Companies. Prior to that, she served as director
of financial planning and analysis (FP&A) at CareFusion, where
she transformed reporting and forecasting processes as the company
stood up operations after the spin-off from Cardinal Health and
guided strategic and operational decisions to support business unit
growth. Ms. Pecora earned a bachelor of science in Finance and a
master of business administration from the University of Maryland's Robert H. Smith School of Business in
College Park.
Mr. Ribar oversees the NuVasive Corporate Finance and Treasury
functions, including FP&A, treasury operations, along with
supporting investor relations. His strong finance and FP&A
experience in the medtech industry includes his most recent
position at Alere, where he led the budgeting, forecasting,
reporting and business analysis for the company before it was
acquired by Abbott Laboratories in October
2017. Prior to that, he was the director of investor
relations at CareFusion where he previously held multiple finance
leadership roles within the organization since its spin-off from
Cardinal Health, as well as leading the finance integration when
the company was acquired by Becton
Dickinson in March 2015. Mr.
Ribar earned a bachelor of science in Business and a master of
business administration from Ohio Dominican
University in Columbus,
Ohio.
Mr. Rosenbaum has been with NuVasive for more than four years
and expands his senior accounting duties to now include serving as
the corporate controller for the Company. He began his accounting
career at Deloitte, and has held a variety of senior accounting
roles at Dura Pharmaceuticals, Elan Pharmaceuticals, Gen-Probe and
Hologic overseeing both internal and external financial reporting.
He graduated with a bachelor of arts in Business Economics from the
University of California, Santa
Barbara.
"With these new leadership appointments, along with the rest of
the finance team, we are building out the depth of the function
through an excellent mix of finance and operations prowess as we
focus on key areas to drive growth for NuVasive," said Raj
Asarpota, executive vice president and chief financial officer of
NuVasive. "Specifically, this growth will be supported by our
insourcing efforts at our manufacturing facility where we will
continue to invest in the processes, tools and people with the
financial expertise in costing and productivity enhancement to
accelerate our profitability."
About NuVasive
NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology
innovation, focused on transforming spine surgery and beyond with
minimally disruptive, procedurally-integrated solutions designed to
deliver reproducible and clinically-proven surgical outcomes. The
Company's portfolio includes access instruments, implantable
hardware, biologics, software systems for surgical planning,
navigation and imaging solutions, magnetically adjustable implant
systems for spine and orthopedics, and intraoperative monitoring
service offerings. With over $1
billion in revenues, NuVasive has an approximate 2,400
person workforce in more than 40 countries serving surgeons,
hospitals and patients. For more information, please visit
www.nuvasive.com.
Forward-Looking Statements
NuVasive cautions you that statements included in this news release
that are not a description of historical facts are forward-looking
statements that involve risks, uncertainties, assumptions and other
factors which, if they do not materialize or prove correct, could
cause NuVasive's results to differ materially from historical
results or those expressed or implied by such forward-looking
statements. The potential risks and uncertainties which contribute
to the uncertain nature of these statements include, among others,
risks associated with acceptance of the Company's surgical products
and procedures by spine surgeons, development and acceptance of new
products or product enhancements, clinical and statistical
verification of the benefits achieved via the use of NuVasive's
products (including the iGA® platform), the Company's ability to
effectually manage inventory as it continues to release new
products, its ability to recruit and retain management and key
personnel, and the other risks and uncertainties described in
NuVasive's news releases and periodic filings with the Securities
and Exchange Commission. NuVasive's public filings with the
Securities and Exchange Commission are available at www.sec.gov.
NuVasive assumes no obligation to update any forward-looking
statement to reflect events or circumstances arising after the date
on which it was made.
View original content with
multimedia:http://www.prnewswire.com/news-releases/nuvasive-announces-key-finance-appointments-300663805.html
SOURCE NuVasive, Inc.